Perrigo Q2 Earnings Call Highlights
Perrigo (PRGO) reported weaker Q2 self-care and specialty-care demand in Europe and lower store-brand minoxidil and Mederma comparisons, while U.S. OTC volumes turned positive in late July. Infant formula revenue rose 23% YoY. Core adjusted gross margin fell 250 bps to 37%. Perrigo sold Dermacosmetics for $359M, using proceeds to reduce debt, and reiterated its 2026 outlook, including about -$0.60 EPS from under-absorption.
How this was made
The 30-second read
Why it matters
Traders can reassess 2026 risk around consumer demand and margin trajectory using the disclosed Q2 margin drivers, the stated under-absorption EPS headwind, and the updated effective tax rate.
Market read
Q2 call highlights combine weaker self-care/specialty margins with infant formula offset, plus maintained full-year guidance and a quantified EPS headwind from under-absorption.
What to watch
The infant formula contract-sales timing benefit is explicitly cautioned as not translating to a higher full-year outlook, and the infant formula/oral care strategic review lacks a timeline, leaving uncertainty.
Background
The piece summarizes Perrigo’s Q2 earnings call, focusing on regional demand, market share, margin drivers, infant formula performance, and balance-sheet actions.
Ticker impact
Perrigo reported Q2 margin declines, maintained 2026 outlook, and guided all-in EPS impact from under-absorption of about $0.60.
Likely choppy reaction risk, with focus on maintained full-year outlook versus weaker core/all-in margins and cautious demand commentary.
The article includes specific Q2 margin and operating income changes plus updated tax rate and share count, but it does not introduce a surprise full-year EPS number or new deal beyond the already-described divestiture and debt reduction.
Market effects
OTC/self-care peers may face similar seasonal demand softness in Europe, but share gains and store-brand momentum could support relative performance.
Europe self-care season delays are cited as a headwind, while U.S. OTC volumes turned positive in late-July.
Infant formula stabilization and optionality reviews may influence investor sentiment toward diversified healthcare suppliers with consumer exposure.
Counterpoint
Share gains and improving category conditions later in the quarter could outweigh the reported margin compression, supporting a rebound narrative into 2H.
Key entities
- companyPerrigo Company plc
NYSE:PRGO, OTC/self-care and infant formula supplier that reported Q2 margin declines and maintained its 2026 outlook.
- business_unitDermacosmetics business
Divested during the quarter for $359 million, with proceeds largely applied to debt reduction.
- business_unitInfant formula business
Revenue up 23% YoY with improved operating income, while Perrigo evaluates optimize, partner, or divest options.
